Patient
P2B-122
completed Phase IIA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · CTRC Institute for Drug Development, University of Texas (San Antonio, TX) (Dr. Muller)
consented 2013-06-12
Adverse events
3
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 3
Grade 1 nausea with onset in cycle 6 (2013-10-09); assessed as not related to study drug (unlikely); resolved 2013-10-14.
Grade 3 aspartate aminotransferase increased with onset in cycle 3 (2013-08-11); assessed as not related to study drug (unlikely); resolved 2013-08-21.
Grade 2 vomiting with onset in cycle 3 (2013-08-05); assessed as not related to study drug (not related); resolved 2013-08-08.
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.